保險股集體走強 中國平安(601318.SH)漲超3%創1個月新高
格隆匯2月25日丨港A兩地保險股集體走強,A股中國太保漲超5%,中國平安漲超3%創1個月新高,新華保險和西水股份漲超2%;港股中國太平和中國太保漲超7%,新華保險和中國平安漲超2%。A股五大上市險企2021年首月保費全部出齊。數據顯示,中國人壽、中國平安、中國人保、中國太保和新華保險五大上市險企1月份合計實現原保險保費收入5615億元,較去年同期增長6.26%,迎來“開門紅”。另外,中金最新報吿稱,中資壽險股春節後跑贏指數,主要因負債端拐點漸近且復甦可能超預期、長端利率上行等,預計未來3-6個月A和H中資壽險板塊的估值修復空間分別有20%和30%。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.